{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-22-000014","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.810260+00:00","generated_at":"2026-06-25T18:40:33.791656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Shattuck Labs Q1 net loss $24.5M ($0.58/shr); cash $239.2M; SL-172154 dose escalation ongoing","bullets":["Net loss $24.5M ($0.58 per share) vs $11.8M ($0.28) YoY; R&D expenses $19.2M, up from $10.3M.","Cash & short-term investments $239.2M as of Mar 31, 2022, down from $321.2M a year ago; runway into 2H2024.","Phase 1 dose escalation of SL-172154 in ovarian cancer continues; full monotherapy data expected 1H2023.","Combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer on track to start 2H2022.","Phase 1 trial of SL-279252 in solid tumors enrolling; top-line data expected 2H2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-22-000014","json":"https://secwatch.observer/filing/0001680367-22-000014.json","markdown":"https://secwatch.observer/filing/0001680367-22-000014.md","text":"https://secwatch.observer/filing/0001680367-22-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/0001680367-22-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/sttk-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:40:33.791656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}